JP2019513015A5 - - Google Patents

Download PDF

Info

Publication number
JP2019513015A5
JP2019513015A5 JP2018547941A JP2018547941A JP2019513015A5 JP 2019513015 A5 JP2019513015 A5 JP 2019513015A5 JP 2018547941 A JP2018547941 A JP 2018547941A JP 2018547941 A JP2018547941 A JP 2018547941A JP 2019513015 A5 JP2019513015 A5 JP 2019513015A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
sequence
acid sequence
actriib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018547941A
Other languages
English (en)
Japanese (ja)
Other versions
JP6987072B2 (ja
JP2019513015A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/021958 external-priority patent/WO2017156488A2/en
Publication of JP2019513015A publication Critical patent/JP2019513015A/ja
Publication of JP2019513015A5 publication Critical patent/JP2019513015A5/ja
Priority to JP2021194152A priority Critical patent/JP7469284B2/ja
Application granted granted Critical
Publication of JP6987072B2 publication Critical patent/JP6987072B2/ja
Priority to JP2023198762A priority patent/JP7755634B2/ja
Priority to JP2025167026A priority patent/JP2026004489A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018547941A 2016-03-10 2017-03-10 アクチビン2型受容体結合タンパク質及びその使用 Active JP6987072B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021194152A JP7469284B2 (ja) 2016-03-10 2021-11-30 アクチビン2型受容体結合タンパク質及びその使用
JP2023198762A JP7755634B2 (ja) 2016-03-10 2023-11-24 アクチビン2型受容体結合タンパク質及びその使用
JP2025167026A JP2026004489A (ja) 2016-03-10 2025-10-03 アクチビン2型受容体結合タンパク質及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662306354P 2016-03-10 2016-03-10
US62/306,354 2016-03-10
PCT/US2017/021958 WO2017156488A2 (en) 2016-03-10 2017-03-10 Activin type 2 receptor binding proteins and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021194152A Division JP7469284B2 (ja) 2016-03-10 2021-11-30 アクチビン2型受容体結合タンパク質及びその使用

Publications (3)

Publication Number Publication Date
JP2019513015A JP2019513015A (ja) 2019-05-23
JP2019513015A5 true JP2019513015A5 (enExample) 2020-04-23
JP6987072B2 JP6987072B2 (ja) 2021-12-22

Family

ID=59790844

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018547941A Active JP6987072B2 (ja) 2016-03-10 2017-03-10 アクチビン2型受容体結合タンパク質及びその使用
JP2021194152A Active JP7469284B2 (ja) 2016-03-10 2021-11-30 アクチビン2型受容体結合タンパク質及びその使用
JP2023198762A Active JP7755634B2 (ja) 2016-03-10 2023-11-24 アクチビン2型受容体結合タンパク質及びその使用
JP2025167026A Pending JP2026004489A (ja) 2016-03-10 2025-10-03 アクチビン2型受容体結合タンパク質及びその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021194152A Active JP7469284B2 (ja) 2016-03-10 2021-11-30 アクチビン2型受容体結合タンパク質及びその使用
JP2023198762A Active JP7755634B2 (ja) 2016-03-10 2023-11-24 アクチビン2型受容体結合タンパク質及びその使用
JP2025167026A Pending JP2026004489A (ja) 2016-03-10 2025-10-03 アクチビン2型受容体結合タンパク質及びその使用

Country Status (19)

Country Link
US (4) US10307455B2 (enExample)
EP (2) EP4465045A3 (enExample)
JP (4) JP6987072B2 (enExample)
KR (4) KR20250142947A (enExample)
CN (2) CN116284392A (enExample)
AU (1) AU2017230091B2 (enExample)
BR (1) BR112018067813A2 (enExample)
CA (1) CA3015277A1 (enExample)
DK (1) DK3426680T3 (enExample)
ES (1) ES2987504T3 (enExample)
FI (1) FI3426680T3 (enExample)
HR (1) HRP20241557T1 (enExample)
HU (1) HUE069467T2 (enExample)
LT (1) LT3426680T (enExample)
PL (1) PL3426680T3 (enExample)
PT (1) PT3426680T (enExample)
RS (1) RS66251B1 (enExample)
SI (1) SI3426680T1 (enExample)
WO (1) WO2017156488A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3015277A1 (en) 2016-03-10 2017-09-14 Acceleron Pharma Inc. Activin type 2 receptor binding proteins and uses thereof
AU2020284038B2 (en) * 2019-05-30 2026-05-14 Acceleron Pharma Inc. ActRII-binding proteins and uses thereof
JP2022549506A (ja) 2019-09-27 2022-11-25 ディスク・メディシン・インコーポレイテッド 骨髄線維症および関連状態を処置するための方法
EP4142769A4 (en) 2020-04-28 2024-05-15 Acceleron Pharma Inc. ACTRII PROTEINS AND USE IN THE TREATMENT OF POSTCAPILLARY PULMONARY HYPERTENSION
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
EP4252782A4 (en) * 2020-11-30 2025-12-10 Cspc Megalith Biopharmaceutical Co Ltd ANTI-CLDN18.2 ANTIBODY, DRUG CONJUGATE, RELATED PREPARATION METHOD AND ASSOCIATED USE
WO2022261436A2 (en) * 2021-06-11 2022-12-15 Acceleron Pharma Inc. Actrii proteins and uses thereof
MX2025002126A (es) 2022-08-26 2025-04-02 Versanis Bio Inc Tratamientos con dosis unitarias fijas del anticuerpo actrii
AU2024317572A1 (en) 2023-07-31 2026-03-12 Sixpeaks Bio Ag Antibody conjugates and fusion proteins

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3546807C2 (enExample) 1985-03-30 1991-03-28 Marc Genf/Geneve Ch Ballivet
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0478627A4 (en) 1989-05-16 1992-08-19 William D. Huse Co-expression of heteromeric receptors
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
PT1696031E (pt) 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
JP4157160B2 (ja) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6696248B1 (en) 1995-08-18 2004-02-24 Morphosys Ag Protein/(poly)peptide libraries
ATE219517T1 (de) 1995-08-18 2002-07-15 Morphosys Ag Protein-/(poly)peptidbibliotheken
WO1997011971A1 (en) 1995-09-28 1997-04-03 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
EP0866805A1 (en) * 1995-12-12 1998-09-30 Karolinska Innovations AB PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
DE69736247T2 (de) 1996-05-20 2007-05-24 Novozymes A/S Verfahren zur herstellung von proteinhydrolysate
US6696251B1 (en) 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ,インコーポレイティド 人工抗体ポリペプチド
US6696260B1 (en) 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
AU8666398A (en) 1997-08-01 1999-02-22 Johns Hopkins University School Of Medicine, The Methods to identify growth differentiation factor (gdf) receptors
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
CA2305712A1 (en) 1997-10-03 1999-04-15 Chugai Seiyaku Kabushiki Kaisha Natural humanized antibody
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
ATE482275T1 (de) 1999-07-02 2010-10-15 Morphosys Ag Erzeugung spezifischer bindungspartner die an von genomischen dns-fragmenten oder ests kodierten (poly)peptiden binden
PA8535501A1 (es) 2001-01-05 2003-07-28 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
HUE026914T2 (en) 2002-11-07 2016-08-29 Immunogen Inc Anti-CD33 antibodies and a method of treating acute myeloid leukemia
US9259459B2 (en) 2003-01-31 2016-02-16 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
JP5110877B2 (ja) 2003-06-02 2012-12-26 ワイス・エルエルシー 神経筋障害を処置するための、コルチコステロイドと組み合わせたミオスタチン(gdf8)インヒビターの使用
WO2005116052A2 (en) 2004-04-27 2005-12-08 Research Development Foundation ANTAGONISM OF TGF-β SUPERFAMILY RECEPTOR SIGNALING
EP3489257A1 (en) 2004-07-23 2019-05-29 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
MX2007000976A (es) 2004-08-12 2007-04-10 Wyeth Corp Tratamiento combinado para diabetes, obesidad y enfermedades cardiovasculares utilizando inhibidores del factor 8 de crecimiento y diferenciacion.
AU2005279347A1 (en) 2004-08-30 2006-03-09 Lonza Biologics Plc. Affinity- plus ion exchange- chromatography for purifying antibodies
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
CA2538208A1 (en) 2005-05-04 2006-11-04 Universite Laval Modulation of myostatin and use thereof in cell transplantation-based treatment of muscle disease
EP1929305A2 (en) 2005-08-31 2008-06-11 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
EP1968621A2 (en) 2005-12-06 2008-09-17 Amgen Inc. Uses of myostatin antagonists
ES2965283T3 (es) 2006-03-15 2024-05-28 Alexion Pharma Inc Tratamiento de pacientes con hemoglobinuria paroxística nocturna mediante un inhibidor del complemento
WO2007109668A2 (en) 2006-03-20 2007-09-27 The Uab Research Foundation Compositions and methods for improving bone mass through modulation of novel receptors of pth and fragments thereof
US20100120627A1 (en) 2006-08-02 2010-05-13 Abdelmajid Belouchi Genemap of the human genes associated with psoriasis
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
CA2677007A1 (en) 2007-02-01 2008-08-07 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating or preventing breast cancer
TW201803890A (zh) 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
EP2481415B1 (en) * 2007-02-09 2019-09-11 Acceleron Pharma Inc. Pharmaceutical compositions comprising Activin-ActRIIA antagonists
US7947646B2 (en) 2007-03-06 2011-05-24 Amgen Inc. Variant activin receptor polypeptides
US20090155275A1 (en) 2007-07-31 2009-06-18 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
EP3124497B1 (en) 2007-09-14 2020-04-15 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8093364B2 (en) 2008-01-18 2012-01-10 Bio-Rad Laboratories, Inc. Enhanced purification of antibodies and antibody fragments by apatite chromatography
JP5470817B2 (ja) 2008-03-10 2014-04-16 日産自動車株式会社 電池用電極およびこれを用いた電池、並びにその製造方法
NZ627111A (en) 2008-11-26 2015-10-30 Amgen Inc Variants of activin iib receptor polypeptides and uses thereof
US8110355B2 (en) 2009-02-20 2012-02-07 GenRemedy, LLC Methods for identifying agents that inhibit cell migration, promote cell adhesion and prevent metastasis
ITAN20090010U1 (it) 2009-04-27 2010-10-28 Arnaldo Sorci Staffa di bloccaggio protettiva
CA2993053A1 (en) * 2009-04-27 2010-11-04 Novartis Ag Antagonistic activin receptor iib (actriib) antibodies for increasing muscle growth
JP6211767B2 (ja) 2009-09-09 2017-10-11 アクセルロン ファーマ, インコーポレイテッド ActRIIbアンタゴニストならびにその投薬および使用
EP2496600A1 (en) * 2009-11-04 2012-09-12 Fabrus LLC Methods for affinity maturation-based antibody optimization
KR102085919B1 (ko) 2009-11-05 2020-03-06 더 리전츠 오브 더 유니버시티 오브 캘리포니아 에칭된 미러들을 구비하는 반극성 {20-21} ⅲ-족 질화물 레이저 다이오드들
US8524217B2 (en) 2010-05-11 2013-09-03 Merck Sharp & Dohme Corp. MCP1-Ig fusion variants
KR102024922B1 (ko) 2010-07-16 2019-09-25 아디맵 엘엘씨 항체 라이브러리
WO2012012759A2 (en) 2010-07-22 2012-01-26 The Regents Of The University Of California Anti-tumor antigen antibodies and methods of use
KR20130132824A (ko) * 2010-11-08 2013-12-05 악셀레론 파마 인코포레이티드 Actriia 결합제 및 이의 용도
TW201249867A (en) 2011-04-01 2012-12-16 Astellas Pharma Inc Novel anti-human il-23 receptor antibody
DK2726099T3 (en) 2011-07-01 2018-11-05 Novartis Ag Method of treating metabolic disorders
BR112014000392A2 (pt) * 2011-07-14 2017-02-21 Pfizer tratamento com anticorpos anti-pcsk9
US8765385B2 (en) * 2011-10-27 2014-07-01 Ravindra Kumar Method of detection of neutralizing anti-actriib antibodies
WO2013063536A1 (en) * 2011-10-27 2013-05-02 Acceleron Pharma, Inc. Actriib binding agents and uses thereof
BR112014015003A2 (pt) 2011-12-19 2019-09-24 Amgen Inc composição farmacêutica, método para tratar um cancer e método para reduzir o tamanho de uma massa tumoral
US9029510B2 (en) 2012-03-30 2015-05-12 Sorrento Therapeutics, Inc. Fully human antibodies that bind to VEGFR2 and methods of use thereof
EA201492282A1 (ru) 2012-06-11 2015-07-30 Амген Инк. Антагонистические антигенсвязывающие белки к двум рецепторам и их применение
JP6136279B2 (ja) 2013-01-15 2017-05-31 株式会社ジェイテクト 転がり軸受装置
JP6049767B2 (ja) 2013-02-01 2016-12-21 株式会社ブリリアントサービス 栽培システム、栽培プログラム、および栽培方法
TWI503850B (zh) 2013-03-22 2015-10-11 Polytronics Technology Corp 過電流保護元件
WO2014172448A2 (en) * 2013-04-17 2014-10-23 Anaptysbio, Inc. Antibodies directed against activin receptor type ii (actrii)
WO2014179363A1 (en) 2013-04-29 2014-11-06 Adimab, Llc Polyspecificity reagents, methods for their preparation and use
CA2918300A1 (en) 2013-08-14 2015-02-19 Novartis Ag Methods of treating sporadic inclusion body myositis
TWI510996B (zh) 2013-10-03 2015-12-01 Acer Inc 控制觸控面板的方法以及使用該方法的可攜式電腦
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
CA2969800A1 (en) 2014-12-08 2016-06-16 Novartis Ag Myostatin or activin antagonists for the treatment of sarcopenia
CA3015277A1 (en) 2016-03-10 2017-09-14 Acceleron Pharma Inc. Activin type 2 receptor binding proteins and uses thereof
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor

Similar Documents

Publication Publication Date Title
JP2024026159A5 (enExample)
AU2021200348B2 (en) Binding molecules with modified J-chain
CN109311971B (zh) 抗TL1A/抗TNF-α双特异性抗原结合蛋白及其用途
TWI767174B (zh) 異二聚免疫球蛋白
KR101852915B1 (ko) 과립구-대식세포 콜로니 자극 인자에 대한 항체
JP2022534966A5 (enExample)
CN115605594A (zh) 抗igf-1受体人源化抗体
TWI815305B (zh) Pd-1/vegf四價雙特異性抗體、其製備方法和用途
CA3064298A1 (en) Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof
WO2021013142A1 (zh) 抗4-1bb抗体、其抗原结合片段及双特异性抗体
JP2019515676A5 (enExample)
KR20230141817A (ko) 이중특이 항체
WO2019080909A1 (en) TARGETING THERAPEUTIC ANTIBODY RANKL
JP2021500895A5 (enExample)
CN113166239B (zh) 抗il-17a抗体及其应用
JP2022534514A5 (enExample)
TW202535947A (zh) CD33抗體、CD33/Vδ2多特異性抗體及其用途
CN115811987A (zh) 抗神经酰胺抗体
AU2023291634C9 (en) Follistatin fusion proteins
US20260109769A1 (en) Pd-1 bnding proteins, vegf and pd-1 bispecific binding proteins, compositions, and methods of use
CN121399157A (zh) 淋巴毒素β受体激动剂结合蛋白
BR122025021892A2 (pt) Células hospedeiras
HK1212719B (zh) 全人源抗rankl抗体